Complications of BCG Immunotherapy in Patients with Cancer

Sparks, Frank C.; Silverstein, Melvin J.; Hunt, John S.; Haskell, Charles M.; Pilch, Yosef H.; Morton, Donald L.

doi:10.1056/nejm197310182891603

Cited by 207 publications

(35 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…has produced fever, malaise, hepatic dysfunction and jaundice, and as there are reports of disseminated BCG infections, there are dangers with its i.v. administration (Bast et al, 1974;Mansell and Krementz, 1973;Pinsky, Hirsthaut and Oettgen, 1972;Sparks et al, 1973). No such side-effects were described with the non-viable MER vaccine.…”

Section: Discussionmentioning

confidence: 99%

A preliminary study of intravenous methanol extraction residue of BCG in treatment of advanced cancer

Robinson¹,

Bartal²,

Honigman³

et al. 1977

Br J Cancer

View full text Add to dashboard Cite

Summary.-Twenty-four patients with advanced cancer not reacting to conventional therapy were treated with 97 courses of i.v. MER (methanol extraction residue of BCG). MER was administered by i.v. infusion over a 4-h period, twice a week, in dosages varying from 0-05 mg to 1 25 mg. The skin reactivity to 5 recall antigens was evaluated in the patients. All patients except 4 were anergic. Twelve patients had no side-effects. Anergic patients had less side-effects than ergic patients. The sideeffects recorded in the others were fever, chills, vomiting and tachycardia. The reaction subsided within 24 h after treatment and was tolerable for most patients.In 2 patients an objective improvement was observed. No changes in cutaneous reactivity, renal and hepatic functions were found. A significant increase in peripheral leucocyte count was noted in two patients and slight a increase in the remainder.

show abstract

Section: Discussionmentioning

confidence: 99%

A preliminary study of intravenous methanol extraction residue of BCG in treatment of advanced cancer

Robinson¹,

Bartal²,

Honigman³

et al. 1977

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The risk of Tuberculosis infection in the solid organ transplant recipients is 20-74 times higher than the general population and the treatment is associated with significant morbidity and mortality [14]. Historical published reports described an increased risk of complications following intralesional injection of BCG vaccine in cancer patients [15,16]. Although, these concerns do exist, there is limited data to support that intravesicle BCG treatment for NMIBC is unsafe or ineffective in the solid organ transplant patients.…”

Section: Current Controversies On Using Intravesicle Bcg In the Transmentioning

confidence: 99%

Intravesicle Bacillus Calmette–Guérin (BCG) Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) in the Transplanted Patients Population: A Systematic Review of the World Literature

Raheem¹,

Eltahawy²,

Davis³

et al. 2015

J Transplant Technol Res

View full text Add to dashboard Cite

Intravesicle Bacille Calmette-Guerin (BCG) is generally considered to be contraindicated in the immunosuppressed or compromised patients with bladder cancer (BC) because of ineffectiveness or partial toxicities. Therefore, there is little experience with BCG in individual with impaired immune system and this can be challenging to practicing urologists. We sought to review the current available evidence of utilizing intravesicle BCG for BC in patients with solid organ transplantation and commented on its current status.

show abstract

“…The complications met with during this type of immunotherapy are well described in the literature [7][8][9][10]. However, a vitiliginous reaction which is considered to present an immune phenomenon [11,12] has rarely been discussed in this connection [13,14].…”

mentioning

confidence: 99%

Vitiligo Associated with BCG-Methanol Extraction Residue in Malignant Melanoma

Cohen¹,

Haim²,

Bartal³

et al. 1979

Dermatology

View full text Add to dashboard Cite

A pronounced vitiliginous reaction developed at the sites of MER/BCG injections given as an adjuvant immunotherapy to a patient with malignant melanoma. To our knowledge, this is the third report on patients exhibiting vitiligo apparently induced by immunotherapy and the first in association with MER. This association may be a sign for an antimelanocytic effect and may offer a further confirmation for the autoimmune nature of vitiligo.

show abstract

Complications of BCG Immunotherapy in Patients with Cancer

Cited by 207 publications

References 18 publications

A preliminary study of intravenous methanol extraction residue of BCG in treatment of advanced cancer

A preliminary study of intravenous methanol extraction residue of BCG in treatment of advanced cancer

Intravesicle Bacillus Calmette–Guérin (BCG) Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) in the Transplanted Patients Population: A Systematic Review of the World Literature

Vitiligo Associated with BCG-Methanol Extraction Residue in Malignant Melanoma

Contact Info

Product

Resources

About